Unknown

Dataset Information

0

Monocyte TREM-1 Levels Associate With Anti-TNF Responsiveness in IBD Through Autophagy and Fcγ-Receptor Signaling Pathways.


ABSTRACT: The expression of Triggering Receptor Expressed on Myeloid cells (TREM)-1 has been described as a predictive marker for anti-Tumor Necrosis Factor (TNF)-α monoclonal antibody (mAb) therapy responsiveness in patients with inflammatory bowel disease (IBD). Here we investigated expression of TREM-1 specifically in CD14+ monocytes in relation to anti-TNF response. The pretreatment TREM-1 expression levels of CD14+ monocytes of Crohn's disease (CD) patients were predictive of outcome to anti-TNF mAb therapy, with low TREM-1 expression associated with response to anti-TNF. FACSorting of CD14+ monocytes with different TREM-1 levels showed that differentiation towards regulatory CD206+ M2 type macrophages by anti-TNF was suppressed in CD14+ monocytes with high TREM-1 expression. Activity of the Fcγ-Receptor and autophagy pathway, both necessary for M2 type differentiation and the response to anti-TNF, were decreased in CD14+ monocytes with high expression of TREM-1. We confirmed that the activity of the Fcγ-Receptor pathway was decreased in the CD patients that did not respond to anti-TNF therapy and that it was negatively correlated with TREM-1 expression levels in the CD patient cohort. In conclusion, our results indicate that TREM-1 expression levels in CD14+ monocytes associate with decreased autophagy and FcγR activity resulting in decreased differentiation to M2 type regulatory macrophages upon anti-TNF mAb treatment, which may explain anti-TNF non-response in IBD patients with high expression levels of TREM-1.

SUBMITTER: Prins MM 

PROVIDER: S-EPMC8005579 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature

altmetric image

Publications

Monocyte TREM-1 Levels Associate With Anti-TNF Responsiveness in IBD Through Autophagy and Fcγ-Receptor Signaling Pathways.

Prins Marileen M MM   Verstockt Bram B   Ferrante Marc M   Vermeire Séverine S   Wildenberg Manon E ME   Koelink Pim J PJ  

Frontiers in immunology 20210315


The expression of <i>Triggering Receptor Expressed on Myeloid cells</i> (<i>TREM)-1</i> has been described as a predictive marker for anti-Tumor Necrosis Factor (TNF)-α monoclonal antibody (mAb) therapy responsiveness in patients with inflammatory bowel disease (IBD). Here we investigated expression of <i>TREM-1</i> specifically in CD14+ monocytes in relation to anti-TNF response. The pretreatment <i>TREM-1</i> expression levels of CD14+ monocytes of Crohn's disease (CD) patients were predictive  ...[more]

Similar Datasets

| S-EPMC4858121 | biostudies-literature
| S-EPMC5542552 | biostudies-literature
| S-EPMC3463630 | biostudies-other
| S-EPMC5974358 | biostudies-literature
| S-EPMC10943853 | biostudies-literature
| S-EPMC7810476 | biostudies-literature
| S-EPMC10871362 | biostudies-literature
| S-EPMC6935410 | biostudies-literature
| S-EPMC4083245 | biostudies-literature
| S-EPMC3762508 | biostudies-literature